Aspirin, omega-3 PUFAs and adenoma detection

Aspirin, omega-3 PUFA fail to reduce adenoma detection rate in high-risk patients
https://www.mdedge.com/gihepnews/article/191860/oncology/aspirin-omega-3-pufa-fail-reduce-adenoma-detection-rate-high-risk
Andrew D. Bowser, MDedge News

Jan 2nd, 2019 - Taking aspirin or an omega-3 polyunsaturated fatty acid daily did not reduce the colorectal adenoma detection rate among high-risk patients in a randomized, placebo-controlled trial, though both drugs showed potential chemopreventive effects. There was no evidence that aspirin, eicosapentaenoic acid (EPA), or the two agents combined had any effect on th.

Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention ... Preview
https://www.ncbi.nlm.nih.gov/pubmed/30466866
Lancet (London, England); Hull MA, Sprange K et. al.

Nov 24th, 2018 - The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) and aspirin both have proof of concept for colorectal cancer chemoprevention, aligned with an excellent safety profile. Therefore, we aimed to test the efficacy of EPA and aspirin, alone and in combination and compared with a placebo, in individuals with sporadic colorectal neoplasia detected at colon...